Hemoglobinopathies Market Overview
According to Market Research Future (MRFR), the global hemoglobinopathies market is projected to rise significantly over the forecast period. The market held a valuation of USD 5.800 million in 2018 and is predicted to experience a CAGR of about 10.2% during forecast period. The report provides a comprehensive overview of the present scenario, the economic condition, and the COVID-19 analysis of the overall market.
Numerous factors are pushing the growth of the global hemoglobinopathies market. Such factors, according to the new Hemoglobinopathies Market Research Future report, include increasing prevalence of blood cancer cases, favorable reimbursement scenario both for diagnostic tests as well as treatment, and innovative approaches such as genetic testing. Additional factors pushing the growth of t hemoglobinopathies market include increasing company and government initiatives to spread awareness about hemoglobin variant diseases, and rising incidence of hemoglobin disorders such as Hb E, Hb C, thalassemia, and sickle cell anemia.
On the contrary, accessibility of diagnostic alternatives of hemoglobinopathies, lack of awareness about diagnoses, and lack of treatment are factors that may hamper the hemoglobinopathies market growth during the forecast period.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8098
Hemoglobinopathies Market Segmentation
- The global market for hemoglobinopathies has been segmented based on type, treatment, and end-users.
- By type, the global market for hemoglobinopathies has been segmented into thalassemia, sickle cell disease, and other Hb variants diseases. Thalassemia is further classified as alpha-thalassemia and beta-thalassemia. The sickle cell disease segment is projected to hold the largest market share of the hemoglobinopathies market. This is due to the existence of robust product pipelines such as Lent Globin and the rising prevalence of sickle cell disease.
- Based on treatment, the global market for hemoglobinopathies has been classified into stem-cell transplantation, blood transfusions, analgesics, antibiotics, ACE inhibitors, and hydroxyurea. The blood transfusion segment holds the largest market share due to a high success rate and the increased acceptance of this treatment option.
- By the end-user, the global market for hemoglobinopathies has been classified into hospitals and clinics, diagnostics laboratories, and others.
Hemoglobinopathies Market Regional Analysis:
By region, the global hemoglobinopathies market report covers the latest trends and growth opportunities across North America, Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will command the largest share in the market during the forecast period as a major part of the populace suffer from sickle cell disease, a common inherited blood disorder. Moreover, the presence of superior-quality healthcare infrastructure, better reimbursement scenario, and increasing investments made by the key players in the research and development activities.
The global hemoglobinopathies market in Europe will hold the second-largest share in the market over the forecast period and will be succeeded by the APAC region that is predicted to grow at the fastest pace during the forecast period. Numerous factors are propelling the growth of hemoglobinopathies market in the region such as increasing incidence of such disorders in the region including Hb E, Hb C, thalassemia, and sickle cell anemia, increasing patient awareness level, and availability of low-cost, indigenously-manufactured diagnostic kits to treat sickle cell disease and thalassemia.
The global hemoglobinopathies market in the MEA will have a small share in the market during the forecast period for low economic development, particularly in the African region.
Hemoglobinopathies Market Players
- Sanofi
- Sangamo Therapeutics, Inc.
- Neusoft Medical Systems Co., Ltd
- Bluebird Bio, Inc.
- Emmaus Life Sciences Inc.
- Prolong Pharmaceuticals
- Global Blood Therapeutics
- Celgene Corporation
- Alnylam Pharmaceuticals
- Gamida Cell
- Acceleron Pharma
- Mast Therapeutic
- HemaQuest Pharmaceuticals
- Invenux
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/hemoglobinopathies-market-8098
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
